

## Special Issue

# Metabolites in Glioma Treatment and Diagnosis

### Message from the Guest Editors

In recent decades, significant advances have established new therapeutic options for treating cancer. However, several major challenges remain unresolved. In particular, gliomas are highly aggressive primary brain tumors. Despite the availability of therapeutic options such as surgery, radiotherapy, and alkylating agent chemotherapy, survival rates remain low. A key issue in these tumors is the presence of metabolic alterations related to the tumor microenvironment, genetic mutations, and other factors. Understanding these alterations is essential, as they may also serve as potential therapeutic targets. The identification, validation, and correlation of these biomolecules represent a promising approach to improving the diagnosis, prognosis, and treatment of this disease. Therefore, this Special Issue will address topics such as the pathophysiology of glioma in relation to metabolite production, the use of metabolites as diagnostic and prognostic markers, novel therapeutic targets associated with metabolites, and cutting-edge technologies for detecting these biomolecules, as well as their potential therapeutic applications.

### Guest Editors

Dr. Rosa Angélica Castillo-Rodríguez

Dr. Gabriela Carrasco-Torres

Dr. María Cristina Trejo-Solís

### Deadline for manuscript submissions

31 May 2026



## Metabolites

an Open Access Journal  
by MDPI

Impact Factor 3.7  
CiteScore 6.9  
Indexed in PubMed



[mdpi.com/si/252595](https://mdpi.com/si/252595)

*Metabolites*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[metabolites@mdpi.com](mailto:metabolites@mdpi.com)

[mdpi.com/journal/  
metabolites](https://mdpi.com/journal/metabolites)





# Metabolites

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.7  
CiteScore 6.9  
Indexed in PubMed



[mdpi.com/journal/  
metabolites](https://mdpi.com/journal/metabolites)



## About the Journal

### Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

---

### Editor-in-Chief

Dr. Amedeo Lonardo  
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).